Merck’s antiviral no better than placebo in cutting hospitalization and death, trials find
According to the results of a pair of large clinical trials, Merck’s experimental antiviral pill failed to lower the risks of COVID-19 hospitalization and death among adults at higher risk from the disease. The company, in partnership with Ridgeback Biotherapeutics. conducted two real-world evidence studies evaluating the drug, molnupiravir, In a trial of more than 25,000 people by researchers at Oxford University, the oral antiviral helped shorten the recovery time of acute infection but showed no substantial benefit compared to taking a placebo in most serious adverse COVID-related events. In a separate study conducted in Israel, real-world data showed that while molnupiravir reduced hospitalizations and mortality due to COVID-19 in patients 65 years and above, “no evidence of benefit was found in younger adults ages 40 to 64 years.” SF Chronicle
molnupiravir was sold in 30 countries
Vitamin D Life Virus pages with PILL in title (4 as of Oct 2022)
This list is automatically updated